Outcomes of a Dispersive Ophthalmic Viscosurgical Device

The aim of this study was to evaluate clinical outcomes related to the protection of corneal endothelial cells and the safety of the Bio-Hyalur CS (Biotech Healthcare Group, Luzern, Switzerland) ophthalmic viscosurgical device (OVD) in routine cataract surgery.

Patients who had undergone cataract surgery using Bio-Hyalur CS as an OVD and who had at least 3 months of follow-up data were included in the study. Endothelial cell density (ECD) and morphology (hexagonality, area, and coefficient of variation in cell size) as well as intraocular pressure were evaluated during 3 months of follow-up. Intraoperative and postoperative complications were recorded.

Sixty eyes of 44 patients were included in the study. The mean preoperative ECD was 2383.5±288.67 cells/mm². The mean postoperative ECD was 2186.0±359.65 cells/mm² and 2149.7±354.49 cells/mm² at 1- and 3-month visits, respectively. The mean coefficient of variation in cell size was 29.1±5.04% and 30.9±5.79% at preoperative and postoperative 3-month visits, respectively. The mean cell area was 426.1±52.59 µm² and 476.6±122.26 µm² at preoperative and postoperative 3-month visits, respectively. No adverse events were reported during the study period.

Bio-Hyalur CS provided good endothelial protection and has a favorable safety profile. However, comparative studies with other OVDs are necessary.